Merck’s Lagevrio (molnupiravir) Missed Primary Endpoints in P-III Trial (MOVe-AHEAD) for Post-Exposure Prophylaxis to Prevent COVID-19
- The P-III trial (MOVe-AHEAD) evaluating Lagevrio (800mg) vs PBO in 1500 patients aged 18yrs. who were free of COVID-19 & lived with someone who was recently diagnosed with the virus
- The trial failed to meet its 1EPs i.e., the therapy did not show a significant reduction in the risk of COVID-19, following household exposure to another individual with COVID-19 while patients with Lagevrio were observed to be 23.6% less likely to develop COVID-19 than PBO @14 Day who did not have evidence of SARS-CoV-2 inf. at baseline
- The safety profile was consistent with prior reported studies & the company plans to submit full results at a scientific meeting. Lagevrio was approved or authorized in multiple markets incl. the US, UK, Australia, China & Japan
Ref: Merck | Image: Merck
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at email@example.com.